Dr. Mark Lawrence Feldman, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 21 Par Ln, Hudson, NH 03051 Phone: 603-459-9057 |
News Archive
W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.
Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.
A new national awards program will recognize teams of critical care professionals and healthcare institutions able to successfully reduce or eliminate healthcare-associated infections (HAI), a leading cause of death in the United States.
A new report from Oxfam and 62 other non-governmental organizations and health groups finds that international goals aiming to reduce child and maternal mortality rates are "desperately off track," with four million babies around the world dying annually within 28 days of birth, Agence France-Press reports (9/13).
› Verified 5 days ago